Hanmi Pharmaceutical

128940 · KOSPI · South Korea

Public Market Listing

128940KOSPI

KOSPI primary exchange listing

Live quotes, historical charts, and market capitalization for Hanmi Pharmaceutical are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(5 total)
5Total Assets
0Approved
1Phase 3 / Filed
4Phase 1–2 / Early
5Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
Phase 3
GLP-1 receptorPeptide
ObesityType 2 Diabetes
Phase 2
GLP-1/GIP/glucagon receptor (triple)Peptide
ObesityMASH / NASH
Phase 2
GLP-1/GIP/glucagon receptor (triple)Peptide
ObesityType 2 Diabetes
Phase 1/2
FLT3 (wild-type and mutant, including ITD/TKD), SYK, JAK1/2, mutant KIT, RSK2Small molecule
Acute Myeloid Leukemia
Entecavir (Cavir)No recent activity
Phase 1
HBV polymerase (reverse transcriptase)Small molecule
Chronic Hepatitis B

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
January 2027 (1)
HM15275Phase 2Obese, Obesity
Est. primary completion 2027-01 · NCT07205900 · CT.gov ↗
What to watch
October 2027 (1)
HM15275Phase 2Type 2 Diabetes Mellitus, T2DM
Est. primary completion 2027-10 · NCT07527650 · CT.gov ↗
What to watch
November 2027 (1)
efpeglenatidePhase 3Type 2 Diabetes
Est. primary completion 2027-11 · NCT07379333 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.1B$161M——report ↗
View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$1.1B$154M$131M—report ↗
2023-FY$1.1B—$43M—report ↗